The Journal of Practical Medicine >
Risk factors and model construction of immune therapy⁃related thyroid dysfunction in non⁃small cell lung cancer
Received date: 2025-04-29
Online published: 2025-09-05
Objective To explore the related risk factors for thyroid dysfunction （irTD） after immunotherapy in patients with non?small cell lung cancer （NSCLC） and to construct a predictive model. Methods A retrospective analysis was conducted on 197 NSCLC patients who received immunotherapy at Chaohu Hospital， Anhui Medical University between January 2019 and June 2024. The patients were divided into a training set （n = 137） and a validation set （n = 60） in a 7∶3 ratio. Risk factors were screened through Lasso and logistic regression， and a dynamic nomogram model was constructed. The model's performance was evaluated using ROC curve， calibration curve， decision curve analysis （DCA）， and clinical impact curve （CIC）. Results Multivariate analysis showed that Gender （OR = 0.172， 95% CI：0.047 ~ 0.623）， M stage（OR = 2.919， 95% CI：1.063 ~ 8.015），ln（SII） （OR = 0.167， 95% CI：0.066 ~ 0.423）， ALC （OR = 3.395， 95% CI：1.493 ~ 7.716）， and TSH （OR = 1.464， 95% CI：1.126 ~ 1.904） were independent risk factors for the occurrence of irTD. The model formula based on these factors is： logit（P） = 9.261 - 1.760 × Gender + 1.071 × M stage - 1.787 × ln（SII） + 1.222 × ALC + 0.381 × TSH. The model achieved an AUC of 0.832（95%CI：0.719 ~ 0.945） in the validation set， which was similar to the results in the training set. The calibration curve demonstrated good consistency between the predicted probability and actual observed values. DCA and CIC confirmed that the model has good clinical applicability. Conclusion This study identifies key risk factors for the occurrence of irTD after immunotherapy in NSCLC patients. The dynamic nomogram model developed （web calculator：
Key words： non?small cell lung cancer; immunotherapy; thyroid dysfunction; nomogram
Lingchun CAO , Fanliang MENG , Xiaoan SHENG . Risk factors and model construction of immune therapy⁃related thyroid dysfunction in non⁃small cell lung cancer[J]. The Journal of Practical Medicine, 2025 , 41(17) : 2705 -2714 . DOI: 10.3969/j.issn.1006-5725.2025.17.014
| [1] | KONG Y， HONG L， XU X C， et al. The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer： Meta-analyses of controlled clinical trials ［J］. PLoS One， 2024， 19（4）： e0301931. doi:10.1371/journal.pone.0301931 |
| [2] | MORATIEL PELLITERO A， ZAPATA GARCIA M， GASCON RUIZ M， et al. Predictors of Immunotherapy Efficacy in Metastatic Non-Small Cell Lung Cancer： Lung Immune Prognostic Index and Immune-Related Toxicity ［J］. World J Oncol， 2024， 15（2）： 223-238. doi:10.14740/wjon1790 |
| [3] | ADASHEK J J， MORAN J A， LE D T， et al. Lessons learned from a decade of immune checkpoint inhibition： The good， the bad， and the ugly ［J］. Cancer Metastasis Rev， 2025， 44（2）： 43. doi:10.1007/s10555-025-10260-8 |
| [4] | TOOR S M， SASIDHARAN NAIR V， DECOCK J， et al. Immune checkpoints in the tumor microenvironment ［J］. Semin Cancer Biol， 2020， 65： 1-12. doi:10.1016/j.semcancer.2019.06.021 |
| [5] | 琴桥西，王稼劲，王红. ICIs治疗晚期非小细胞肺癌免疫相关不良事件的系统综述及Meta分析 ［J］. 中国肺癌杂志， 2020， 23（9）： 772-791. |
| [6] | ZHANG H， ZHENG J， REN C， et al. Risk factors of immune-related endocrine toxicities in non-small cell lung cancer patients treated with pembrolizumab and its impact on patient outcomes： A multicenter retrospective study ［J］. BMC Pulm Med， 2025， 25（1）： 111. doi:10.1186/s12890-025-03570-8 |
| [7] | LIU J， CHEN M， LI S， et al. Biomarkers in the early stage of PD-1 inhibitor treatment have shown superior predictive capabilities for immune-related thyroid dysfunction ［J］. Front Immunol， 2024， 15： 1458488. doi:10.3389/fimmu.2024.1458488 |
| [8] | ZHANG Q， JIAO X， LAI X. Clinical Characters and Influence Factors of Immune Checkpoint Inhibitor-related Thyroid Dysfunction ［J］. J Clin Endocrinol Metab， 2023， 108（11）： 2916-2923. doi:10.1210/clinem/dgad260 |
| [9] | HAMNVIK O P， LARSEN P R， MARQUSEE E. Thyroid dysfunction from antineoplastic agents ［J］. J Natl Cancer Inst， 2011， 103（21）： 1572-1587. doi:10.1093/jnci/djr373 |
| [10] | 李冰， 谷伟军， 母义明. 免疫检查点抑制剂致甲状腺损伤的规范化诊治 ［J］. 中华内科杂志， 2024， 63（11）： 1116-1119. |
| [11] | 倪军， 张力， 肿瘤免疫治疗相关不良反应研究进展 ［J］. 中华内科杂志， 2021， 60（1）： 84-89. |
| [12] | 吴小茜，江燕辉，刘美伶，等. 恶性乳腺非肿块型病变超声特征分析及列线图预测模型构建［J］. 实用医学杂志，2023，39（1）：119-123. |
| [13] | CHEN L， FU H， LU T， et al. An Integrated Nomogram Combining Clinical Factors and Microtubule-Associated Protein 1 Light Chain 3B Expression to Predict Postoperative Prognosis in Patients with Intrahepatic Cholangiocarcinoma ［J］. Cancer Res Treat， 2020， 52（2）： 469-480. doi:10.4143/crt.2019.423 |
| [14] | BALACHANDRAN V P， GONEN M， SMITH J J， et al. Nomograms in oncology： More than meets the eye ［J］. Lancet Oncol， 2015， 16（4）： e173-180. doi:10.1016/s1470-2045(14)71116-7 |
| [15] | ZHANG L， CUI H， CHEN Q， et al. A web-based dynamic Nomogram for predicting instrumental activities of daily living disability in older adults： A nationally representative survey in China ［J］. BMC Geriatr， 2021， 21（1）： 311. doi:10.1186/s12877-021-02223-9 |
| [16] | TRIGGIANESE P， NOVELLI L， GALDIERO M R， et al. Immune checkpoint inhibitors-induced autoimmunity： The impact of gender ［J］. Autoimmun Rev， 2020， 19（8）： 102590. doi:10.1016/j.autrev.2020.102590 |
| [17] | DUNN S E， PERRY W A， KLEIN S L. Mechanisms and consequences of sex differences in immune responses ［J］. Nat Rev Nephrol， 2024， 20（1）： 37-55. doi:10.1038/s41581-023-00787-w |
| [18] | FORSYTH K S， JIWRAJKA N， LOVELL C D， et al. The conneXion between sex and immune responses ［J］. Nat Rev Immunol， 2024， 24（7）： 487-502. doi:10.1038/s41577-024-00996-9 |
| [19] | 安豪，裴晓莎，何心，等. PD-1抑制剂治疗的晚期非小细胞肺癌患者甲状腺功能异常发生情况及影响因素［J］. 山东医药，2024，64（32）：33-37. |
| [20] | 王一博，王新娟，程琳，等. 晚期非小细胞肺癌患者应用免疫治疗后出现甲状腺功能异常与疗效的相关性分析［J］. 中国肺癌杂志，2023，26（5）：369-376. |
| [21] | SAKATA Y， KAWAMURA K， ICHIKADO K， et al. The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment ［J］. Lung Cancer， 2019， 130： 159-161. doi:10.1016/j.lungcan.2019.02.011 |
| [22] | GAO Y， ZHANG H， LI Y， et al. Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer ［J］. Clin Chim Acta， 2018， 484： 272-277. doi:10.1016/j.cca.2018.05.059 |
| [23] | SHAO H， ZHU J， SHI L， et al. Value of computed tomography radiomics combined with inflammation indices in predicting the efficacy of immunotherapy in patients with locally advanced and metastatic non-small cell lung cancer ［J］. J Thorac Dis， 2024， 16（5）： 3213-3227. doi:10.21037/jtd-24-526 |
| [24] | KIMBARA S， FUJIWARA Y， IWAMA S， et al. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab ［J］. Cancer Sci， 2018， 109（11）： 3583-3590. doi:10.1111/cas.13800 |
| [25] | POLLACK R M， KAGAN M， LOTEM M， et al. BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI-PD-1-INDUCED THYROID DYSFUNCTION ［J］. Endocr Pract， 2019， 25（8）： 824-829. doi:10.4158/ep-2018-0472 |
| [26] | LUONGO C， MORRA R， GAMBALE C， et al. Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy ［J］. J Endocrinol Invest， 2021， 44（9）： 1927-1933. doi:10.1007/s40618-021-01508-5 |
| [27] | MUIR C A， CLIFTON-BLIGH R J， LONG G V， et al. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment ［J］. J Clin Endocrinol Metab， 2021， 106（9）： e3704-e3713. doi:10.1210/clinem/dgab263 |
| [28] | CORTELLINI A， FRIEDLAENDER A， BANNA G L， et al. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes ［J］. Clin Lung Cancer， 2020， 21（6）： 498-508.e2. doi:10.1016/j.cllc.2020.06.010 |
/
| 〈 |
|
〉 |